Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
11.86
+0.42 (3.67%)
May 12, 2025, 4:00 PM - Market closed
Exicure Employees
Exicure had 7 employees as of December 31, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
$71,429
Profits / Employee
-$1,385,857
Market Cap
74.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
XCUR News
- 7 days ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 weeks ago - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - Business Wire
- 4 weeks ago - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - Business Wire
- 7 weeks ago - Exicure, Inc. Reports Full Year 2024 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
- 3 months ago - CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Business Wire
- 3 months ago - Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Business Wire
- 4 months ago - Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Business Wire